Mild cognitive impairment (MCI) causes memory impairment and executive function deficits in those with the condition. There is also some evidence that MCI patients are impaired in their daily functioning. Cholinesterase inhibitors have been widely used for patients with Alzheimer's disease (AD), with evidence of improving cognitive function. There is currently no established treatment for MCI, and cholinesterase inhibitors are beginning to be studied in these patients. Galantamine is a cholinesterase inhibitor that also has nicotinic receptor-modulating properties that has been successful in improving AD patients. This study examined the effects of galantamine in patients with MCI in areas of memory, executive functioning, and global functioning. There was a significant improvement in scores on the Functional Activities Questionnaire, which is a measure of global functioning. There were also improvements in the galantamine group on two of six measures in the Cambridge Automated Neuropsychiatric Test Assessment Battery and in immediate free recall on the California Verbal Learning Test.
Laurrieu S, Letenneur L, Orgogozo JM, et al.: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002; 59(10): 1594-1599.
2.
Davie J, Azuma T, Goldinger SD: Sensitivity to expectancy violations in healthy aging and mild cognitive impairment. Neuropsychology. 2004; 18(2): 269-275.
3.
Olin J, Schneider L, Novit A, et al.: Hydergine for dementia. Cochrane Database Syst Rev. 2000;(2): CD000359-CD000359. Review.
4.
Wilcock GK, Lilienfeld S, Gaens E, et al.: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000; 321(7274): 1445-1449.
5.
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatr. 2001; 71: 589-595.
6.
Herrmann N: Pharmacotherapy for Alzheimer's disease and other dementias. Curr Opin Psychiatr. 2002; 15(4): 403-409.
7.
Petersen R, Smith G, Waring S, et al.: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999; 56(3): 303-308.
8.
Morris JC, Storandt M, Miller JP, et al.: Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001; 58: 397-405.
9.
Thal LJ: Therapeutics and mild cognitive impairment: Current status and future directions. Alzheimer Dis Assoc Disord. 2003; 17(Suppl 2): S69-S71.
Luis CA, Loewenstein DA, Acevedo A, et al.: Mild cognitive impairment: Directions for future research. Neurology. 2003; 61: 438-444.
12.
Davis, HS, Rockwood K: Conceptualization of mild cognitive impairment: A review. Int J Geriatr Psychiatr. 2004; 19(4): 313-319.
13.
Petersen RC, Thomas RG, Grundman M, et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352: 2379-2388.
14.
Salloway S, Ferris S, Kluger A, et al.: Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology. 2004; 63(4): 651-657.
15.
Barnes CA, Meltzer J, Houston F, et al.: Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience. 2000; 99(1): 17-23.
16.
Newhouse PA, Potter A, Singh A: Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol. 2004; 4: 36-46.
17.
Deutsch SI, Rosse RB, Deutsch LH et al.: A galantamine mechanism primer. Geriatric Times. 2004; 5(1): 98-102.
18.
Albuquerque EX, Alkondon M, Pereiria EF, et al.: Properties of neural nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997; 280(3): 1117-1136.
19.
Albuquerque EX, Pereiria EF, Mike A, et al.: Neuronal nicotinic receptors in synaptic function in humans and rats: Physiological and clinical relevance. Behavior Brain Res. 2000; 113(1-2): 131-141.
20.
Cummings JL, Schneider L, Tariot PN, et al.: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatr. 2004; 161: 532-538.
21.
Wong DF, Scheffel U, Fan H, et al.: Imaging the mechanism of action in the biodistribution of galantamine and other potential allosteric potentiating ligands for dementia treatment. SFN abstract. 2002. Available online at: http://sfn.scholarone.com/itin2002/index.html.
22.
Samochocki M, Zerlin M, Jostock R, et al.: Galantamine is an allosterically potentiating ligand of the human a4/b2 nAChR. Acta Neurol Scand Suppl. 2000; 176: 68-73.
23.
Yatsula MA, Fu Y, Sharp BM: Effect of galantamine on nicotineinduced catecholamine release in hippocampus (HP) and nucleus accumbens (NACC) of rats: An in vivo microdialysis study. SFN abstracts. 2003. Available online at: http://sfn.scholarone.com/itin2003/index.html.
24.
Maelicke A: Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000; 11(Suppl 1): 11-18.
25.
Caramelli P, Chaves MLF II, Engelhardt E III, et al.: Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: Results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01). Arq Neuropsiquiatr. 2004; 62(2b): 379-384.
26.
Coyle J, Kershaw P: Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol Psychiatr. 2001; 49(3): 289-299.
27.
Petersen RC: Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist. 1995; 1: 326-344.
28.
Pfeffer RI, Kurosaki TT, Harrah CH Jr, et al.: Measurement of functional activities in older adults in the community. J Gerontol. 1982; 37(3): 323-329.
29.
Thibault JM, Steiner RWP: Efficient identification of adults with depression and dementia. Am Fam Phys. 2004; 70: 1101-1110.
